Previous close | 4.90 |
Open | 5.01 |
Bid | 5.03 x 300 |
Ask | 5.10 x 200 |
Day's range | 4.99 - 5.26 |
52-week range | 1.43 - 6.85 |
Volume | |
Avg. volume | 604,267 |
Market cap | 262.209M |
Beta (5Y monthly) | 2.65 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.88 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.60 |
The mean of analysts' price targets for Black Diamond Therapeutics (BDTX) points to a 95.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BDTX Advances in Oncology with Key Clinical Trials and Maintains Strong Cash Position
Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients with acquired resistance or non-classical EGFRm NSCLC Oral presentation at AACR annual meeting in April 2024 describing real world evidence of an evolving EGFR mutation landscape in NSCLC, and the potential of BDTX-1535 to benefit patients across multiple lines of therapy Additional planned data releases for 2024 include